500293-29-8
500287-72-9
[1]JournalofMedicinalChemistry,2005,vol.48,p.2072-2079
[2]Patent:US9192577,2015,B2.Locationinpatent:Page/Pagecolumn73-74
374067-85-3
500287-72-9
[1]JournalofMedicinalChemistry,2005,vol.48,p.2072-2079
[2]Patent:WO2004/16581,2004,A1.Locationinpatent:Page24
[3]Patent:US9192577,2015,B2.Locationinpatent:Page/Pagecolumn67-68
[1]JournalofMedicinalChemistry,2005,vol.48,p.2072-2079
[2]Patent:US9192577,2015,B2
[1]JournalofMedicinalChemistry,2005,vol.48,p.2072-2079
[1]JournalofMedicinalChemistry,2005,vol.48,p.2072-2079
[2]JournalofMedicinalChemistry,2005,vol.48,p.2072-2079
[3]Patent:WO2013/179105,2013,A1
Title: Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabine.
Journal: Antimicrobial agents and chemotherapy 20140401
Title: Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
Journal: Bioorganic & medicinal chemistry 20140315
Title: In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
Journal: Antimicrobial agents and chemotherapy 20140301
Title: Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
Journal: Bioorganic & medicinal chemistry letters 20140201
Title: In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.
Journal: Antimicrobial agents and chemotherapy 20131101
Title: Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
Journal: Bioorganic & medicinal chemistry letters 20130915
Title: Update on rilpivirine: a new potent non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV replication.
Journal: Annals of medicine 20130501
Title: Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
Journal: International journal of antimicrobial agents 20130501
Title: Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Journal: Journal of medicinal chemistry 20121213
Title: Biochemical mechanism of HIV-1 resistance to rilpivirine.
Journal: The Journal of biological chemistry 20121102
Title: Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20121001
Title: Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
Journal: Clinical drug investigation 20121001
Title: E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.
Journal: AIDS (London, England) 20120824
Title: Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.
Journal: Journal of medicinal chemistry 20120823
Title: Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1 and bevirimat-resistant HIV-1 variants.
Journal: Bioorganic & medicinal chemistry letters 20120815
Title: Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.
Journal: HIV medicine 20120801
Title: Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
Journal: Biochemical pharmacology 20120801
Title: Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Journal: The Journal of antimicrobial chemotherapy 20120801
Title: New drugs 2012, part 2.
Journal: Nursing 20120701
Title: Baseline E138 reverse transcriptase resistance-associated mutations in antiretroviral-naive HIV-infected patients.
Journal: AIDS (London, England) 20120601
Title: Rilpivirine: a second-generation nonnucleoside reverse transcriptase inhibitor.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120515
Title: Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial.
Journal: AIDS research and human retroviruses 20120501
Title: Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
Journal: Journal of acquired immune deficiency syndromes (1999) 20120501
Title: Rilpivirine: a next-generation non-nucleoside analogue for the treatment of HIV infection.
Journal: Expert opinion on pharmacotherapy 20120501
Title: Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20120401
Title: Rilpivirine.
Journal: Drugs 20120305
Title: Prevalence of TMC278 (rilpivirine) associated mutations in the Frankfurt Resistance Database.
Journal: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20120301
Title: The HIV-1 reverse transcriptase M184I mutation enhances the E138K-associated resistance to rilpivirine and decreases viral fitness.
Journal: Journal of acquired immune deficiency syndromes (1999) 20120101
Title: Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis.
Journal: Journal of acquired immune deficiency syndromes (1999) 20120101
Title: Boceprevir, telaprevir, and rilpivirine hydrochloride.
Journal: Journal of the American Pharmacists Association : JAPhA 20120101
Title: Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects.
Journal: Antiviral therapy 20120101
Title: Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
Journal: Journal of medicinal chemistry 20111222
Title: Design and synthesis of pyridone inhibitors of non-nucleoside reverse transcriptase.
Journal: Bioorganic & medicinal chemistry letters 20111215
Title: Update of the past year: a review from IDSA 2011.
Journal: Topics in antiviral medicine 20111201
Title: Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
Journal: Drugs 20111112
Title: FDA notifications. Complera approved.
Journal: AIDS alert 20111101
Title: Rilpivirine (Edurant)--a new drug for HIV infection.
Journal: The Medical letter on drugs and therapeutics 20110822
Title: HIV/AIDS and the road to Rome.
Journal: Lancet (London, England) 20110716
Title: Rilpivirine: a step forward in tailored HIV treatment.
Journal: Lancet (London, England) 20110716
Title: Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Journal: Lancet (London, England) 20110716
Title: Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
Journal: Lancet (London, England) 20110716
Title: Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H.
Journal: Journal of medicinal chemistry 20110714
Title: Rilpivirine: a new addition to the anti-HIV-1 armamentarium.
Journal: Drugs of today (Barcelona, Spain : 1998) 20110101
Title: Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Journal: Antiviral therapy 20110101
Title: Rilpivirine and complera: new first-line treatment options.
Journal: BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation 20110101
Title: Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
Journal: Antiviral chemistry & chemotherapy 20100811
Title: Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100601
Title: Bioequivalent formulation for the fixed-dose regimen of Truvada and TMC278 finalized.
Journal: AIDS patient care and STDs 20100601
Title: Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.
Journal: Journal of medicinal chemistry 20100527
Title: Conformational populations of ligand-sized molecules by replica exchange molecular dynamics and temperature reweighting.
Journal: Journal of computational chemistry 20100501
Title: TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
Journal: Antimicrobial agents and chemotherapy 20100201
Title: [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Journal: Yao xue xue bao = Acta pharmaceutica Sinica 20100201
Title: Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.
Journal: AIDS (London, England) 20100102
Title: Drug interactions with new and investigational antiretrovirals.
Journal: Clinical pharmacokinetics 20100101
Title: Molecular dynamics study of non-nucleoside reverse transcriptase inhibitor 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (TMC278/rilpivirine) aggregates: correlation between amphiphilic properties of the drug and oral bioavailability.
Journal: Journal of medicinal chemistry 20091008
Title: Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20090915
Title: Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.
Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090801
Title: Second complete once-daily single tablet therapy in development.
Journal: AIDS patient care and STDs 20090801
Title: Rilpivirine: a novel non-nucleoside reverse transcriptase inhibitor.
Journal: Expert opinion on investigational drugs 20090701
Title: Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
Journal: Pharmacotherapy 20090301
Title: Development of a liquid chromatographic assay for an anti-HIV tablet containing lamivudine, zidovudine and TMC278.HCL.
Journal: Journal of pharmaceutical and biomedical analysis 20090220
Title: Short-term randomized proof-of-principle trial of TMC278 in patients with HIV type-1 who have previously failed antiretroviral therapy.
Journal: Antiviral therapy 20090101
Title: Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies.
Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20081101
Title: Ninety-six week data released on TMC278.
Journal: AIDS patient care and STDs 20081001
Title: Researcher presents vexing information on rilpivirine.
Journal: Project Inform perspective 20080901
Title: Rilpivirine, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection.
Journal: Current opinion in investigational drugs (London, England : 2000) 20080801
Title: Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data.
Journal: Current opinion in drug discovery & development 20080701
Title: New drugs.
Journal: Journal of HIV therapy 20080601
Title: Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
Journal: European journal of medicinal chemistry 20070501
Title: NNRTI data in naive patients.
Journal: AIDS patient care and STDs 20070401
Title: Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
Journal: AIDS (London, England) 20060822
Title: Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
Journal: Current opinion in investigational drugs (London, England : 2000) 20060201
Title: HIV Pathogenesis and Treatment - Third International AIDS Society Conference.
Journal: IDrugs : the investigational drugs journal 20051001
Title: [New drugs--hope for salvage patients?].
Journal: MMW Fortschritte der Medizin 20050425
Title: In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
Journal: Journal of medicinal chemistry 20050324
Title: Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
Journal: Journal of medicinal chemistry 20050324
Title: A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.
Journal: Antimicrobial agents and chemotherapy 20041001
Title: Behind 'AIDS breakthrough' headlines, December 2004: important research, not so new.
Journal: AIDS treatment news 20040101
Title: Janssen PAJ, et, al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[-[-[(1E)-2-cyanoethenyl-2,6-dimethylphenylamino-2- pyrimidinylaminobenzonitrile (R278474, rilpivirine). J Med Chem. 2005 Mar 24;48(6):1901-9.
Title: Azijn H, et, al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother. 2010 Feb;54(2):718-27.
